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Rationale
The aim of the treatment of osteoarthritis (OA) is to improve
symptoms and function; ideally, treatment would also pre-
vent the structural progression of the disease. The targets
of structure-modifying OA drugs (STMOADs) can be one of
the various lesions of OA, including cartilage destruction,
osteophytes, bone sclerosis, cysts, and bone attrition.
However, prevention of cartilage destruction (chondro-
protection) is currently accepted as the most promising
target of STMOADs.
The possibility of preventing progression of cartilage
damage has been demonstrated in various animal models
of OA. Chondroprotection is now being investigated in
human OA. Several trials are in progress, and two positive
studies have already been reported1,2. The goal of these
initial trials was mainly to demonstrate that a reduction of
the natural progression of OA joint space narrowing is
possible in humans. Today, chondroprotection is no longer
considered a myth, and the questions now are whether
STMOADs provide a clinical benefit for the patient and how
to evaluate that benefit. These new and relevant questions
are difficult to answer.
Can we expect a clinical benefit from
STMOADs?
Drugs evaluated for a structure-modifying effect may or
may not also have symptomatic effects in the short term.
STMOADs with a symptomatic effect can be expected to
lead to clinical improvement in the OA patient in the
long term. Evaluation of the clinical benefit of STMOADs
could be possible with the tools presently used for the
assessment of symptom-modifying drugs in OA.
The clinical benefit that can be expected from a drug
without known symptomatic effects but with a structure-
modifying effect and how to measure that clinical benefit
are as yet unknown. An effective STMOAD is not expected
to induce a repair of the structural lesions of OA, but it is
expected to stop or decrease their progression. Such a
structural effect in the long term might result in symptom
improvement or might only prevent a progression of symp-
toms. It also might have no clinical effect, since symptoms
and lesions are poorly correlated in OA patients.
The time required to demonstrate the clinical benefit of a
STMOAD is unknown. It is possible that there may be a
long delay (several years) between the beginning of
STMOAD efficacy and the realization of any clinical benefit.
The extent of clinical benefit could be related to the degree
of effectiveness of the STMOAD. If this were true, the delay
in clinical benefit could be very long for drugs able to only
partially reduce the structural progression of the disease.
Finally, the clinical benefit of a STMOAD might be missed
by our usual tools and could require new methods of
evaluation.
Pain and function measurement for the
demonstration of the clinical benefit of a
STMOAD
Numerous tools used for the clinical measurement of the
OA patient have been validated in short-term trials of
symptom-modifying drugs. These tools rely mainly on the
measurement of pain and function, either separately or in
composite indices (e.g., Lequesne index, WOMAC scale).
Their reliability and sensitivity to change in long-term
studies are poorly known. However, they represent valid
methods for demonstrating the clinical benefit of
STMOADs. The use of quality-of-life questionnaires could
be of special interest for such trials.
Are there more appropriate tools for the
demonstration of the clinical benefit of a
STMOAD?
Stabilization of the clinical status of the OA patient by
preventing progression of structural lesions of the disease
could be the major clinical benefit of a STMOAD. However,
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other methods of evaluation of the clinical benefit of a
STMOAD could be imagined. The need for other medical
treatments of OA, especially invasive or expensive treat-
ments and those with harmful side effects, could be of
interest as clinical end-points. Other end-points could in-
clude the need to reduce activity because of functional
impairment, the need for devices to aid mobility, such as a
cane, and the requirement for joint replacement surgery.
Total hip replacement (THR) has been proposed as an
outcome measure of hip OA3. THR, sooner or later, is the
final treatment for a majority of patients with hip OA. THR is
indicative of both a high level of painful handicap and a late
pathological stage. Requirement for THR is also a simply
measured end-point. However, the time for surgery is
partially related to various factors independent of OA:
patient psychology, physician psychology, age, associated
diseases, economic systems. The effect of these factors
could be reduced by using the time when the physician or
the patient would estimate that surgery would be justified
rather than the time of the surgery itself. Total joint replace-
ment is relatively less common in knee OA than in hip OA.
Thus, requirement for surgery of the OA knee would
probably be a less usable method of evaluation than THR.
The design of a study with THR as a primary outcome
measure would be complex since only patients expected to
need surgery during the course of the study would be
selected. This contrasts with chondroprotection trials,
which rely on measurement of the progression of joint
space narrowing so that patients expected to need surgery
must be excluded.
Trial design for the demonstration of the clinical
benefit of a STMOAD
A study designed to demonstrate both a structure-
modifying effect and a clinical effect will probably differ from
a study designed only to demonstrate a structural effect.
For example, selection of patients with regard to pain or
handicap level would be different. In a chondroprotection
trial, the patients studied must have enough cartilage to
permit measurement of its destruction rate, clinical status
being of marginal interest. A chondroprotection trial that
also aims to demonstrate a clinical benefit would require
patients who had not only an adequate amount of cartilage
but also enough pain and/or impairment to make possible
assessment of clinical improvement. In later trials, cessa-
tion of any analgesic or non-steroidal anti-inflammatory
drug (NSAID) intake prior to clinical evaluation would also
be imperative for the accurate evaluation of a clinical
benefit.
The method of calculating the number of patients per
group would also be different. The number of patients for a
chondroprotection study is based on the natural rate of
progression of joint space narrowing. Determining the
number of patients needed to demonstrate a clinical benefit
of treatment would require some knowledge of the natural
rate of progression of symptoms in OA patients (e.g., in
patients enrolled in a placebo-controlled trial). Definition of
a clinically aggravated patient, as well as the percentage of
aggravated patients per year, could be of interest for the
design of a trial aimed at the demonstration of a clinical
benefit of a STMOAD.
Summary
Evaluation of the clinical benefit of a structure-modifying
OA drug is a question of major interest. The evaluations
performed in a study of both a structure-modifying effect
and a clinical benefit will differ from those performed in a
simple trial of chondroprotection. Existing tools used for the
clinical measurement of OA patients may be of help in
evaluating the clinical efficacy of STMOADs, or it may be
that the clinical benefits of STMOADs will be missed by
conventional tools and require new methods of evaluation.
Appendix
Abbreviations used in the manuscript:
NSAID non-steroidal anti-inflammatory drug
OA osteoarthritis
STMOAD structure-modifying osteoarthritis drug
THR total hip replacement
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